Sanofi is building on its immunology ambitions by acquiring an early clinical Dren Bio drug candidate that offers a potential first-in-class approach to autoimmune disorders such as lupus. It’s the latest acquisition in what has become an active space for dealmaking.
Ouro Medicines’ drugs deplete disease-driving immune cells, allowing the immune system to reset with naïve cells that don’t attack the body. Monograph Capital founded the startup in partnership with GSK.
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
Merck is acquiring global rights to a bispecific antibody from LaNova Medicines that blocks two cancer targets, PD-1 and VEGF. The deal comes one day after BioNTech announced an $800 million acquisition that gives it full rights to a molecule in this hot class of cancer drug candidates.
Merck is acquiring a Curon Biopharmaceuticals drug whose encouraging Phase 1 data were presented during the ASCO annual meeting. The pharmaceutical giant sees potential applications of the bispecific antibody in cancer and autoimmune disease.
Johnson & Johnson is acquiring a bispecific antibody that Numab Therapeutics engineered to address two pathways associated with the inflammation and itching of atopic dermatitis. It’s J&J’s second immunology acquisition this month.
Amgen’s Imdelltra has FDA approval in extensive-stage small cell lung cancer, making it the first bispecific T cell engager approved for treating this type of cancer. Analysts project the new Amgen drug will become a blockbuster seller.
Outsourcing your medical coding can help ensure a healthy revenue cycle. Discover the best medical coding outsourcing companies and find the right one for you.
The FDA approved Roche’s Columvi as a third-line treatment for a type of blood cancer called diffuse large B-cell lymphoma. This new Roche drug will compete against Epkinly, AbbVie’s recently approved DLBCL drug.
Jazz Pharmaceuticals is paying Zymeworks $50 million up front for rights to develop zanidatamab, a bispecific antibody cancer drug currently in two pivotal clinical trials. It’s the second bispecific antibody pact of the week, following Gilead Sciences’ deal to secure an option on a MacroGenics drug in early clinical development.
Artificial intelligence and machine learning are key to 3T Biosciences’ approach to identifying novel drug targets and engineering better, safer cancer immunotherapies. The Stanford spinout is now out of stealth with a $40 million Series A financing and a plan to reach the clinic within two years.
Follicular lymphoma patients in Europe now have a new treatment option. The European Commission approved Roche drug Lunsumio, a bispecific antibody designed to go after two targets to treat advanced cases of this type of cancer.
Every wellness clinic is only as successful as the capabilities of its software. Here's where you can find the top-rated practice management solutions for med spas.
The company presented data from a Phase I study in acute myeloid leukemia at the European Hematology Association's annual meeting during the summer.
It remains unclear how many patients will relapse without the BCMA antigen, which would complicate their ability to use many CAR-T cell therapies later on. However, an expert said the drug's safety could be a challenge.
The hold had been placed in February following two deaths in the study, including one in a patient who experienced cytokine release syndrome. The company has amended the trial protocol to mandate monitoring and management of CRS.
The company sees its platform as potentially overcoming off-target toxicities in existing antibody-drug conjugates, bispecific antibodies and solid tumor CAR-Ts.